HGF and breast cancer: The disruption of hepatocyte growth factor (HGF)/c-MET signaling is a potential targeted approach to treating metastatic bone disease, and the combinatorial use of Tivantinib and zoledronic acid has yielded promising therapeutic results in a preclinical animal model of bone metastasis of breast cancer [64].